Main Article Content


Inflammatory bowel disease (IBD) is a chronic condition characterized by prolonged inflammation of gastrointestinal tract. Repeated damage to the gut mucosa with disruption of the intestinal barrier function is a key feature of IBD, leading to the development of deep ulcerations, fistulas, strictures, and abscesses. In clinical developments, healing of the damaged mucosa has emerged as a key therapeutic goal in the clinical management of IBD. It is associated with better long-term patient outcome, reduced risk of relapse, decreased hospitalization rates and steroid-free remission in IBD patients. Mucosal healing is traditionally being achieved by systemic delivery of aminosalicylates, corticosteroids, sulfasalazine, anti TNF-á. Despite being effective, these drugs are inadequate to prevent or reverse the damage and often cause off-target systemic side effects and malignancies. However, emerging tissue engineering, regenerative medicines and stem cell technologies provide new opportunities to develop better therapeutic options for IBD patients. The aim of this review is to shed light on those emerging technologies that specifically target the diseased tissues by minimally invasive methods and locally deliver drugs, or stem cells to achieve regeneration of diseased or damaged tissues of the intestinal tract that


inflammatory bowel disease Crohn's disease ulcerative colitis mucosal healing tissue engineering air brush spraying

Article Details

How to Cite
Mairal, A., & Kumar*, A. (2021). Emerging Mechanistic Approaches for Mucosal Healing and Regeneration in Inflammatory Bowel Disease. Trends in Biomaterials & Artificial Organs, 35(5), 519-526. Retrieved from